Research
Molecular
The reductions in TG levels persisted at 26 weeks with a mean treatment difference of -12.7% compared to placebo.
ω-3-PL/FFA may provide long-term benefits in managing TG levels.
StrongSupportsmedium confidence
Reductions persisting at 26 weeks (mean treatment difference, -12.7% [95% CI, -23.1% to -2.4%]; P = .02).
Why this rating
Based on the large randomized controlled trial design.
Source
Effectiveness of a Novel ω-3 Krill Oil Agent in Patients With Severe Hypertriglyceridemia
Dariush Mozaffarian et al. · JAMA Network Open · 2022
DOI 10.1001/jamanetworkopen.2021.41898
rct · n=520Cited 24×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Molecular
- QRISK decreased markedly after weight loss from 18.9 ± 2.2% to 11.2 ± 1.6%, p < 0.0001.Strong
- Normalization of 10-year cardiovascular risk and heart age is possible after substantial dietary weight loss and remission of T2DM.Strong
- The Low-Fat Plus diet resulted in a greater reduction in total cholesterol compared to the Low-Fat diet, with changes of -0.46 mmol/L (-17.6 mg/dL) versus -0.24 mmol/L (-9.2 mg/dL) respectively (P = 0.01).Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →